Please use this identifier to cite or link to this item:
http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/3385
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ekici, Berkay | - |
dc.contributor.author | Yaman, Mehmet | - |
dc.contributor.author | Kucuk, Murathan | - |
dc.contributor.author | Dereli, Seckin | - |
dc.contributor.author | Yenercag, Mustafa | - |
dc.contributor.author | Yigit, Zerrin | - |
dc.contributor.author | Bas, Mehmet Memduh | - |
dc.contributor.author | Karavelioglu, Yusuf | - |
dc.contributor.author | Cakmak, Huseyin Altug | - |
dc.contributor.author | Kivrak, Tarik | - |
dc.contributor.author | Ozkan, Hakan | - |
dc.contributor.author | Altin, Cihan | - |
dc.contributor.author | Sabanoglu, Cengiz | - |
dc.contributor.author | Demirkan, Burcu | - |
dc.contributor.author | Atas, Ali Ekber | - |
dc.date.accessioned | 2023-01-06T10:46:48Z | - |
dc.date.available | 2023-01-06T10:46:48Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Ekici, B., Yaman, M., Kucuk, M., Dereli, S., Yenercag, M., Yigit, Z., Bas, MM., Karavelioglu, Y., Cakmak, HA., Kivrak, T., Ozkan, H., Altin, C., Sabanoglu, C., Demirkan, B., Atas, AE., Kilicaslan, F., Altay, H., Tengiz, I., Erkan, AF., Kilicaslan, B., Olgun, FE., Durakoglugil. (2021). Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR). Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 49(5), 357-.Doi:10.5543/tkda.2021.63099 | en_US |
dc.identifier.isbn | 1016-5169 | - |
dc.identifier.uri | http://dx.doi.org/10.5543/tkda.2021.63099 | - |
dc.identifier.uri | https://www.webofscience.com/wos/woscc/full-record/WOS:000672534200004 | - |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/34308869 | - |
dc.identifier.uri | http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/3385 | - |
dc.description | WoS Categories : Cardiac & Cardiovascular Systems Web of Science Index : Emerging Sources Citation Index (ESCI) Research Areas : Cardiovascular System & Cardiology Open Access Designations : gold | en_US |
dc.description.abstract | Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. Methods: The ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. Results: N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARNi. Conclusion: The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | TURKISH SOC CARDIOLOGY BAHCELIEVLER | en_US |
dc.relation.isversionof | 10.5543/tkda.2021.63099 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | SACUBITRIL/VALSARTAN IMPROVES; ENALAPRIL; DISEASE | en_US |
dc.subject | Angiotensin receptor neprilysin inhibitor; heart failure with reduced ejection fraction; sacubitril; valsartan; real-world | en_US |
dc.title | Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR) | en_US |
dc.type | article | en_US |
dc.relation.journal | TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY | en_US |
dc.contributor.department | Ordu Üniversitesi | en_US |
dc.contributor.authorID | 0000-0002-0933-7852 | en_US |
dc.contributor.authorID | 0000-0002-8156-2675 | en_US |
dc.identifier.volume | 49 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 357 | en_US |
Appears in Collections: | Dahili Tıp Bilimleri |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.